文献速递系统性红斑狼疮

给予CXCL5通过髓系与中性粒细胞途径减轻小鼠狼疮炎症并改善生存

Dampened Inflammation and Improved Survival After CXCL5 Administration in Murine Lupus via Myeloid and Neutrophil Pathways.
PubMed 文献 · Arthritis Rheumatol · 2023-02-22

在SLE患者和Faslpr小鼠中检测CXCL5表达,并在Faslpr小鼠中经静脉给予CXCL5以观察疗效与机制。SLE患者血清CXCL5显著低于健康人且与疾病活动度负相关;给药可恢复循环CXCL5、改善小鼠生存并降低抗双链DNA抗体、蛋白尿及狼疮肾炎活动与慢性化指数等指标。

要点

  • SLE患者血清CXCL5水平显著低于健康人(P < 0.0001),且与疾病活动度负相关(P = 0.004)。
  • Faslpr小鼠静脉给予CXCL5可恢复内源性循环CXCL5、改善生存并降低抗双链DNA抗体、蛋白尿和狼疮肾炎活动与慢性化指数。
  • CXCL5在体外和体内调控中性粒细胞转运并抑制其活化、脱颗粒、增殖和肾脏浸润。

核心结论

  • SLE患者血清CXCL5水平显著低于健康人,且与疾病活动度负相关。
  • 在狼疮小鼠模型中静脉给予CXCL5可改善小鼠生存并显著降低疾病活动度指标。
  • 作者认为给予CXCL5可能代表一种新的靶向髓系/中性粒细胞的SLE疗法。

研究设计与样本

  • 研究检测SLE患者与Faslpr小鼠血液及Faslpr小鼠主要内脏器官中的CXCL5表达,方法包括Luminex、实时聚合酶链反应和免疫荧光染色。
  • 在Faslpr小鼠和健康Institute of Cancer Research小鼠中进行药代动力学研究。
  • 在Faslpr小鼠中验证给予CXCL5的疗效,并通过流式细胞术、Luminex和RNA测序阐明机制。

主要发现

  • SLE患者血清CXCL5水平显著低于健康个体(P < 0.0001),且与疾病活动度负相关(P = 0.004)。
  • Faslpr小鼠疾病严重度随年龄进展,并与血浆CXCL5水平负相关。
  • Faslpr小鼠静脉给予CXCL5可恢复内源性循环CXCL5、改善小鼠生存,并降低抗双链DNA抗体、蛋白尿、狼疮肾炎活动指数与慢性化指数、肾脏补体及中性粒细胞胞外诱捕网,短期(10周)和长期(2年)时段均观察到。
  • 体外和体内实验显示CXCL5决定中性粒细胞转运并抑制其活化、脱颗粒、增殖和肾脏浸润。
  • 肾脏和脾脏RNA测序显示CXCL5介导的免疫调节通过促进肾脏浸润免疫细胞的能量产生、激活某些T细胞以及减少组织纤维化、粒细胞外渗、补体成分和干扰素实现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the efficacy of CXCL5 administration in lupus-prone MRL/lpr (Faslpr ) mice and elucidate its working mechanisms. METHODS: CXCL5 expression in blood (obtained from SLE patients and Faslpr mice) and major internal organs (obtained from Faslpr mice) was examined by Luminex, real-time polymerase chain reaction, and immunofluorescent staining analyses. Pharmacokinetic studies were performed in Faslpr mice and healthy Institute of Cancer Research mice. Efficacy of CXCL5 administration was demonstrated in Faslpr mice, and the working mechanism of CXCL5 treatment was elucidated by flow cytometry, Luminex, and RNA sequencing. RESULTS: In SLE patients, serum CXCL5 levels were significantly lower than in healthy individuals (P < 0.0001) and negatively correlated with disease activity (P = 0.004). In Faslpr mice, disease severity progressed with age and was negatively associated with plasma CXCL5 levels. Intravenous administration of CXCL5 to Faslpr mice restored endogenous circulatory CXCL5, improved mice survival, and reduced anti-double-stranded DNA antibodies, proteinuria, lupus nephritis activity and chronicity indices, renal complements, and neutrophil extracellular traps over short-term (10 weeks) and long-term (2 years) time periods. In vitro and in vivo assays demonstrated that CXCL5 dictated neutrophil trafficking and suppressed neutrophil activation, degranulation, proliferation, and renal infiltration. Renal and splenic RNA sequencing further showed that CXCL5-mediated immunomodulation occurred by promoting energy production in renal-infiltrated immune cells, activating certain T cells, and reducing tissue fibrosis, granulocyte extravasation, complement components, and interferons. Further factorial design results indicated that CXCL5 appears to enhance host tolerability to cyclophosphamide in vulnerable individuals. CONCLUSION: We found that serum CXCL5 levels were significantly lower in SLE patients than in healthy individuals and were negatively correlated with disease activity. By administering CXCL5 intravenously in a mouse model of lupus, mouse survival improved, and indices of disease activity reduced significantly. Taken together, these findings indicate CXCL5 administration may represent a novel myeloid/neutrophil-targeting therapy for SLE.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Fan X, Ng CT, Guo D, et al. Dampened Inflammation and Improved Survival After CXCL5 Administration in Murine Lupus via Myeloid and Neutrophil Pathways. Arthritis Rheumatol. 2023. PMID: 36240108. doi:10.1002/art.42383

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。